To print: Select File and then Print from your browser's menu

Title: Fluoxetine Treatment For Depression Should Continue For Set Period For Proper Assessment

URL: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=R
Retrieve&db=PubMed&list_uids=12668363&dopt=Abstract

Am J Psychiatry 2003 Apr;160:4:734-40. "When should a trial of fluoxetine for major depression be declared failed?"
04/09/2003 10:23:16 AM
By David Ball

Patients with major depression who are being treated with fluoxetine should continue therapy for eight weeks before non-response is pronounced, say researchers in the United States. Little is known about how long it takes for the widely used newer antidepressants to show their full effect so trial length should be discussed by clinicians and their patients at the start of therapy. This is suggested by F. M. Quitkin and colleagues at the Columbia University, New York State Psychiatric Institute. In their 12-week open trial of fluoxetine involving data on 840 patients, the researchers tested the number of weeks treatment should continue with no improvement before it was changed. A blinded, placebo-controlled discontinuation study followed the trial treatment of 20 mg a day fluoxetine. Based on Hamilton Depression Rating Scale scores, outcomes were classified as non-response, partial response, response and remission at 4, 6, 8, 10 and 12 weeks. At week 12 the rate of remission was calculated for each group of subjects with no remission at the previous time points. In the discontinuation study, the time to relapse during weeks 13 to 26 was checked in those taking placebo and fluoxetine in relation to status at week 6. A remission rate of 31 to 41% was found in subjects who were unimproved at week 6. The level of improvement at week 6 was seen not to affect prognosis in weeks 13 to 26 in patients with remission at week 12. For those who were unimproved at week 8, 23% were found to have remissions by week 12. Continued treatment was clearly justified for those subjects who were unimproved at week 4 by the high remission rate in week 12. For unimproved patients at week 10, however, the rate was too low.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=R
Retrieve&db=PubMed&list_uids=12668363&dopt=Abstract

Copyright © 2009 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content.